🇮🇳 Promising practice-changing data from @TataMemorial India 🇮🇳 at #ESMO2026!
Phase III trial (n=475) in technically unresectable oral cancer:
Weekly paclitaxel-carboplatin + oral metronomic therapy (PCm) vs DCF

✅ Higher response rates
✅ Greater conversion to resectability
✅ Significantly less toxicity
✅ Non-inferior overall survival
✅ Outpatient-friendly, without central line

2-year OS: 38.9% vs 29.4%, favouring PCm.

An innovative, pragmatic, potentially more accessible and cost effective regimen from India!

👏 Congratulations @VanitaNoronha and the entire team from @TataMemorial

#ESMO26 @OncoAlert @oncodaily @myESMO @montypal @neerajaiims